Table 3:
Human papillomavirus vaccine history and unadjusted rate ratios among cervical intraepithelial neoplasia grade 3 or worse (CIN3+) cases and matched controls, Kaiser Permanente 1996–2014
|
Cases n=1,849 |
Controls n=9,242 |
||||
|---|---|---|---|---|---|
| N | (%) | N | (%) | RR (95% CI)1 | |
| HPV vaccine history | |||||
| Prior vaccination | 154 | (8) | 893 | (10) | 0.82 (0.68–1.00) |
| No prior vaccination | 1,695 | (92) | 8,349 | (90) | 1 (reference) |
| HPV vaccine history, age at first dose | |||||
| Prior vaccination, 14–17 years | 22 | (1) | 188 | (2) | 0.45 (0.27–0.76) |
| Prior vaccination, 18–20 years | 56 | (3) | 312 | (3) | 0.84 (0.59–1.21) |
| Prior vaccination, ≥21 years | 76 | (4) | 393 | (4) | 0.92 (0.73–1.17) |
| No prior vaccination | 1,695 | (92) | 8,349 | (90) | 1 (reference) |
| HPV vaccine history, # doses | |||||
| Prior vaccination, ≥3 doses2 | 71 | (4) | 486 | (5)) | 0.68 (0.52–0.90) |
| Prior vaccination, 2 doses | 36 | (2) | 168 | (2) | 1.02 (0.71–1.48) |
| Prior vaccination, 1 dose | 47 | (3) | 239 | (3) | 0.94 (0.68–1.30) |
| No prior vaccination | 1,695 | (92) | 8,349 | (90) | 1 (reference) |
| HPV vaccine history, age at first dose, # doses | |||||
| Prior vaccination, 14–17 years, ≥3 doses | 10 | (1) | 126 | (1) | 0.29 (0.14–0.60) |
| Prior vaccination, 18–20 years, ≥3 doses | 20 | (1) | 132 | (1) | 0.67 (0.41–1.10) |
| Prior vaccination, ≥21 years, ≥3 doses | 41 | (2) | 228 | (2) | 0.88 (0.62–1.25) |
| Prior vaccination, 14–17 years, <3 doses | 12 | (1) | 62 | (1) | 0.77 (0.40–1.49) |
| Prior vaccination, 18–20 years, <3 doses | 22 | (1) | 93 | (1) | 1.08 (0.66–1.75) |
| Prior vaccination, ≥21 years, <3 doses | 49 | (3) | 252 | (3) | 0.95 (0.70–1.30) |
| No prior vaccination | 1,695 | (92) | 8,349 | (90) | 1 (reference) |
1
Based on bivariate conditional logistic regression models
2
No cases and 4 controls had four or more vaccine doses